Blood test for humira levels could personalize arthritis care
NCT ID NCT01382160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 69 adults with rheumatoid arthritis who were taking the drug adalimumab (Humira). Researchers measured drug levels in the blood over 6 months to see if they could predict who would respond well to treatment. The goal was to find a way to adjust doses early, improving results and reducing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHR d'Orléans
Orléans, France
-
CHR du Mans
Le Mans, France
-
CHRU de Brest
Brest, France
-
CHRU de Nantes
Nantes, France
-
CHRU de Poitiers
Poitiers, France
-
CHRU de Rennes
Rennes, France
-
CHRU de Tours
Tours, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?